SHORT REPORTSAerosol α1 -antitrypsin treatment for cystic fibrosis
References (8)
- et al.
Cystic fibrosis
The imbalance between granulocyte neutral proteases and antiproteases in bronchial secretions from patients with cystic fibrosis
- et al.
Complement receptor expression on neutrophils at an inflammatory site, the pseudomonas infected lung in cystic fibrosis
J Clin Invest
(1989)
Cited by (312)
Protease-anti-protease compartmentalization in SARS-CoV-2 ARDS: Therapeutic implications
2022, eBioMedicineCitation Excerpt :In summary, this study demonstrates that AAT responses to SARS-CoV-2 infection are compartmentalized with an appropriate increase in plasma and alveoli but deficient responses in airways (Figure 7). These data suggest administration of intravenous or aerosolized AAT to SARS-CoV-2- infected subject airways may be an appropriate therapeutic option.32,33 Finally, according to these data, caution should be exercised in SARS-CoV-2-infected individuals with respect to administration of IL-6 blocking therapies.
Novel Immunomodulatory Therapies for Respiratory Pathologies
2022, Comprehensive PharmacologyAlpha-1 antitrypsin for cystic fibrosis complicated by severe cytokinemic COVID-19
2021, Journal of Cystic FibrosisA specialized method of sputum collection and processing for therapeutic interventions in cystic fibrosis
2019, Journal of Cystic FibrosisCitation Excerpt :Sputum NE has also been shown to correlate with bronchiectasis on CT scan [25]. Furthermore, sputum biomarkers have been used in the assessment of anti-inflammatory therapeutics in CF. However, many of these studies did not achieve significant changes in sputum for inflammatory endpoints including NE activity [26–45], despite significant effects in similar studies using BAL [20, 22, 46–48]. Indeed, many clinically relevant trials assessing potential anti-inflammatory therapies and inflammatory therapeutic targets in CF have opted not to use sputum [49–61].
Cystic fibrosis
2019, Emery and Rimoin's Principles and Practice of Medical Genetics and Genomics: Cardiovascular, Respiratory, and Gastrointestinal Disorders